TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00253643

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea catechin extract
Description: Given orally 2 times/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea catechin extract
Description: Given orally 2 times/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: Given orally 3 times/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: Given orally 3 times/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given olive oil placebo orally 3 times/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given olive oil placebo orally 3 times/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given green tea placebo orally 2 times/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given green tea placebo orally 2 times/day
Study: NCT02462668

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bag-mask ventilation
Description: The control group receives preoxygenation with bag-mask ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation(NIPPV)
Description: The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fibreoptic bronchoscopy assisted intubation
Description: All patients will receive fibreoptic bronchoscopy assisted intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fibreoptic bronchoscopy assisted intubation
Description: All patients will receive fibreoptic bronchoscopy assisted intubation.
Study: NCT04191330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiovitalsHF
Description: BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
Study: NCT01778439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-52M51
Study: NCT03862352

Intervention type: DEVICE
Intervention: Covered coronary stent
Description: Insertion of covered coronary stent as part of standard care
Study: NCT02527369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP1100RF
Description: Treatment of adipose tissue within the fat layer with XP1100RF device.
Study: NCT02710838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrared endoscopy
Description: Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.

Intervention type: DEVICE
Group type: OTHER
Intervention: infrared endoscopy
Description: Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
Study: NCT01786096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD19A
Description: SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
Study: NCT01431196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccination
Description: Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
Study: NCT03829319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsule once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching lenvatinib
Description: Oral capsule once daily
Study: NCT02779959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine
Study: NCT00807742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Treatment (NRT)
Description: Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Treatment (NRT)
Description: Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Advice
Description: Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Contingent Reinforcement
Description: Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
Study: NCT03339011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational SMS text message
Description: Motivational text messages delivered to the participants' mobile phones. The text messages contain motivational text and advice on physical activity.
Study: NCT00873340

Intervention type: DRUG
Intervention: Interferon-1beta (Betaseron, BAY86-5046)
Description: Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
Study: NCT01300169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Collaborative Assessment and Management of Suicidality
Description: Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care as Usual
Description: This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
Study: NCT01241799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided fine needle aspiration biopsy
Description: 22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stylet out FNA first, Stylet in FNA second
Description: 22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
Study: NCT04149015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel ,oxaliplatin,fluorouracil
Description: A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
Study: NCT04170439

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene plus metformin plus N acetyle cysteine in arm number 1
Description: oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene citrate plus metformin with chromium
Description: oral adminstration of clomiphene citrate plus metformin and chromium

Intervention type: DRUG
Group type: OTHER
Intervention: clomiphene citrate plus metformin
Description: oral adminstration of clomiphene citrate plus metformin
Study: NCT02381405

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enterade beverage
Study: NCT04013529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regret lottery
Description: Subjects who achieve step goals are entered into a lottery in which they can win a financial incentive of $30 or $100.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Way to Health technology enhanced care
Description: Subjects receive text reminders to reach activity goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Way to Health technology enhanced care
Description: Subjects receive text reminders to reach activity goals.
Study: NCT03159091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rengalin
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study: NCT02319187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S1 80mg to 120 mg per day on Days 1-14, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S1 80mg to 120 mg per day on Days 1-10, every 14 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan 160mg/m2 d1, every 14 days
Study: NCT02446431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus \[an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)\] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
Study: NCT03558984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-PLEX
Description: D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice.
Study: NCT04405687

Intervention type: PROCEDURE
Intervention: Severe head and face deformity reconstructive surgery
Description: Three questionnaires, including the 36-Item Short Form Health Survey questionnaire (SF-36), Aesthetic and Functional Status Score of Facial Soft-Tissue Deformities/Defects (A\&F) and Euroqol 5 dimensions 5 levels questionnaire (EQ-5D-5L), were conducted to evaluate their quality of life and satisfaction with facial aesthetic and functional status.
Study: NCT01518218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laying-on-of-hands
Description: The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
Study: NCT02594969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleach Bath and Moisturizers
Description: All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bleach Bath and Moisturizers
Description: All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
Study: NCT03817554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
Study: NCT04933604

Intervention type: PROCEDURE
Intervention: laparoscopic partial nephrectomy
Description: Nephron sparing minimally invasive surgery

Intervention type: PROCEDURE
Intervention: Laparoscopic radical nephrectomy
Description: Completely removal of kidney by using laparoscopic surgery
Study: NCT02959528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: n-back training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: perceptual training
Description: visual-perceptual training program
Study: NCT04378816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision making support tool
Description: Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
Study: NCT03236220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine
Description: Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
Study: NCT04338009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of ARB/ACEI
Description: The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of ARB/ACEI
Description: The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).
Study: NCT04644939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions and a telephone call one day before the procedure to re-explain the instructions and the importance of bowel preparation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard bowel preparation
Description: Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Patients will undergo colonoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Patients will undergo colonoscopy
Study: NCT02839265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT3 Ligand Therapy (CDX-301)
Description: See Arm 1 descriptions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: See Arm 1 descriptions
Study: NCT01787942

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tear Science LipiView
Description: The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tear Science LipiView
Description: The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
Study: NCT01935778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine and oxaliplatin
Description: Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
Study: NCT01112839

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Less Intensive
Description: Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.